FDA lifts par­tial clin­i­cal hold on In­nate's can­cer drug af­ter pa­tient death linked to dis­ease pro­gres­sion

The FDA has lift­ed a par­tial clin­i­cal hold on In­nate Phar­ma’s IND for its po­ten­tial can­cer drug la­cu­tam­ab af­ter it first im­posed the hold in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.